A Phase 1 Trial of Cabazitaxel Combined With 188Re-Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment: The ReCab Trial

作者：van Dodewaard de Jong Joyce M; Bouman Wammes Esther W^*; Bloemendal Haiko J; Verheul Henk M W; de Klerk John M H; van den Eertwegh Alfons J M

来源：Clinical Nuclear Medicine, 2017, 42(6): 415-420.

DOI：10.1097/RLU.0000000000001604

• Re-188-HEDP
• cabazitaxel
• metastatic CRPC
• radiopharmaceutical

Purpose In patients with metastatic castration-resistant prostate cancer (mCRPC), bone-seeking radiopharmaceuticals, such as Re-188-hydroxyethylidene diphosphonate (HEDP), are effective for pain palliation and have a marked antitumor effect. Cabazitaxel is the standard second-line chemotherapy for mCRPC patients. We performed a phase 1 study investigating the safety and feasibility of the combined treatment with Re-188-HEDP and cabazitaxel in mCRPC patients.
Methods Patients with mCRPC and documented disease progression on or after docetaxel were eligible for inclusion. In both dose levels, cabazitaxel (4 cycles of cabazitaxel 25 mg/m(2) + 2 cycles of cabazitaxel 20 mg/m(2) in level 1, and 6 cycles of cabazitaxel 25 mg/m(2) in level 2) were combined with 2 cycles of Re-188-HEDP 40 MBq/kg (1.1 mCi/kg) (after the second and fourth cabazitaxel cycles). Three patients were planned for each dose level, expanding to 6 patients in case of a dose-limiting toxicity (DLT). A DLT is defined as any grade 4 toxicity, or grade 3 toxicity delaying the next treatment cycle.
Results Twelve patients were included, of whom 3 had progressive disease before the third cycle of cabazitaxel. In total, 1 DLT occurred (dose level 1) after treatment cycle 6 (Re-188-HEDP) (thrombopenia grade 3 delaying the next treatment cycle). The cohort was expanded to 6 patients, with no further DLTs. No DLT occurred in dose level 2. The most important adverse events were of hematologic origin, followed by mild fatigue and diarrhea.
Conclusions Combination therapy with cabazitaxel and Re-188-HEDP is feasible and generally well tolerated with similar hematologic toxicity compared with cabazitaxel monotherapy.

• 出版日期2017-6